{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:38:36Z","timestamp":1780994316505,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejmech.2017.07.044","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T20:47:21Z","timestamp":1500756441000},"page":"865-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5707-966X","authenticated-orcid":false,"given":"Murugaiah A.M.","family":"Subbaiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Meanwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Kadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.07.044_bib1","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/13543784.2016.1212837","article-title":"Investigational protease inhibitors as antiretroviral therapies","volume":"25","author":"Midde","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2017.07.044_bib3","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/ph7040433","article-title":"Amino acid prodrugs: an approach to improve the absorption of HIV-1 protease inhibitor","volume":"7","author":"Patel","year":"2014","journal-title":"Lopinavir, Pharm. (Basel)"},{"key":"10.1016\/j.ejmech.2017.07.044_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.48.3.791-798.2004","article-title":"Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir","volume":"48","author":"Furfine","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2017.07.044_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0091270007313392","article-title":"Effects of acid-reducing agents on the pharmacokinetics of lopinavir\/ritonavir and ritonavir-boosted atazanavir","volume":"48","author":"Klein","year":"2008","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.044_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1468-1293.2007.00496.x","article-title":"Steady-state pharmacokinetics of once-daily fosamprenavir\/ritonavir and atazanavir\/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers","volume":"8","author":"Luber","year":"2007","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2017.07.044_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/0091270010367651","article-title":"Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects","volume":"51","author":"Zhu","year":"2011","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.044_bib9","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/jps.23193","article-title":"Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir","volume":"101","author":"Wang","year":"2012","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.07.044_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.107.017483","article-title":"Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats","volume":"36","author":"Usansky","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.07.044_bib11","first-page":"10","article-title":"Positioning of HIV-protease inhibitors in clinical practice","volume":"16","author":"Andreoni","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2017.07.044_bib12","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2017.07.044_bib13","series-title":"FDA Website: Prescription Information","year":"2017"},{"key":"10.1016\/j.ejmech.2017.07.044_bib14","unstructured":"Predicted data of ACD\/Labs were obtained from online by searching the name of the individual PI: www.chemspider.com (accessed 17.07.17)."},{"key":"10.1016\/j.ejmech.2017.07.044_bib15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2174\/0929867321666140217115951","article-title":"Advances in non-peptidomimetic HIV protease inhibitors","volume":"21","author":"Pang","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17425247.2014.913566","article-title":"Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in\u00a0vitro\/in\u00a0vivo characterization","volume":"11","author":"Singh","year":"2014","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.ejmech.2017.07.044_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00003495-200060020-00016","article-title":"Saquinavir soft-gel capsule","volume":"60","author":"Figgitt","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2017.07.044_bib18","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm4007998","article-title":"Using deuterium in drug discovery: leaving the label in the drug","volume":"57","author":"Gant","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib19","series-title":"Azapeptide Derivatives","author":"Harbeson","year":"2012"},{"key":"10.1016\/j.ejmech.2017.07.044_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drudis.2013.08.014","article-title":"Chemistry-enabled drug delivery (prodrugs): recent progress and challenges","volume":"19","author":"Clas","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2017.07.044_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs\u2013from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.07.044_bib22","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2017.07.044_bib23","unstructured":"D. Melisi, M.G. Rimoli, (Eds.), Recent Developments in Prodrug Design: Drug Targeting, Pharmacological and Pharmacokinetic Improvements Related to a Reduction of Adverse Effects. [In: Curr. Top. Med. Chem. (Sharjah, United Arab Emirates), 2011; 11(18)], Bentham Science Publishers, Ltd., 2011."},{"key":"10.1016\/j.ejmech.2017.07.044_bib24","unstructured":"J. Rautio, (Ed.), Prodrugs And Targeted Delivery: Towards Better ADME Properties. [In: Methods Princ. Med. Chem., 2011; 47], Wiley-VCH Verlag GmbH & Co. KGaA, 2011."},{"key":"10.1016\/j.ejmech.2017.07.044_bib25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2174\/1381612033454441","article-title":"Prodrugs of HIV protease inhibitors","volume":"9","author":"Vierling","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2017.07.044_bib26","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2174\/1568026033451763","article-title":"Strategies in the design of prodrugs of anti-HIV agents","volume":"3","author":"Calogeropoulou","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2006.12.011","article-title":"In\u00a0vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation","volume":"336","author":"Brouwers","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib28","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/jm900080g","article-title":"Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir","volume":"52","author":"DeGoey","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib29","series-title":"Preparation of Lysine-based Compounds Which Release an HIV Protease Inhibitor","author":"Stranix","year":"2006"},{"key":"10.1016\/j.ejmech.2017.07.044_bib30","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.addr.2012.10.001","article-title":"Amino acids as promoieties in prodrug design and development","volume":"65","author":"Vig","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.07.044_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1211\/0022357055786","article-title":"Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents","volume":"57","author":"Pereira de Oliveira","year":"2005","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.044_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2005.06.017","article-title":"Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification","volume":"303","author":"Jain","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2008.06.013","article-title":"Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux","volume":"362","author":"Jain","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2006.11.058","article-title":"Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats","volume":"336","author":"Jain","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpharm.2008.03.031","article-title":"Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor","volume":"359","author":"Agarwal","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib36","series-title":"Preparation of Peptidyl HIV Prodrugs Which Are Cleavable by CD26","author":"De Kock","year":"2004"},{"key":"10.1016\/j.ejmech.2017.07.044_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1039\/B313119J","article-title":"Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity","volume":"2","author":"Gaucher","year":"2004","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib38","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.ejmech.2007.08.016","article-title":"Synthesis and in\u00a0vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors","volume":"43","author":"Roche","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/mp0500768","article-title":"Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery","volume":"3","author":"Luo","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2011.05.001","article-title":"Targeting SVCT for enhanced drug absorption: synthesis and in\u00a0vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir","volume":"414","author":"Luo","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.07.044_bib41","series-title":"Prodrugs of HIV Protease Inhibitors Utilizing a Transporter-directed Uptake Mechanism","author":"Gerk","year":"2013"},{"key":"10.1016\/j.ejmech.2017.07.044_bib42","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1021\/bc060210m","article-title":"Synthesis and in\u00a0vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport","volume":"17","author":"Roche","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib43","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2174\/092986707782360123","article-title":"Application of the O-N intramolecular acyl migration reaction in medicinal chemistry","volume":"14","author":"Skwarczynski","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bmc.2003.10.026","article-title":"Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O-->N intramolecular acyl migration: design, synthesis and kinetic study","volume":"12","author":"Hamada","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib45","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/S0960-894X(03)00463-3","article-title":"Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety","volume":"13","author":"Kazmierski","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.07.044_bib46","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1021\/jm049344g","article-title":"No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions","volume":"48","author":"Skwarczynski","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/978-0-387-73657-0_223","article-title":"Application of intramolecular migration reaction in peptide chemistry to chemical biology, chemical pharmaceutics and medicinal chemistry","volume":"611","author":"Hayashi","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2017.07.044_bib48","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/jm030009m","article-title":"Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage","volume":"46","author":"Sohma","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib49","series-title":"Substituted Carbamates as HIV Protease Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of HIV Infection, AIDS and AIDS-related Conditions","author":"McLean","year":"2006"},{"key":"10.1016\/j.ejmech.2017.07.044_bib50","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bmcl.2006.01.035","article-title":"Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385","volume":"16","author":"Miller","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.07.044_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejmech.2013.02.001","article-title":"Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs","volume":"63","author":"Velthuisen","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/bc0498875","article-title":"Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay","volume":"15","author":"Gunaseelan","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2017.07.044_bib53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1073\/pnas.0805375106","article-title":"FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in\u00a0vivo","volume":"106","author":"Marinec","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.07.044_bib54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/157016208784324967","article-title":"Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir","volume":"6","author":"Cherry","year":"2008","journal-title":"Curr. HIV Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T21:25:30Z","timestamp":1535577930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417305664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":54,"alternative-id":["S0223523417305664"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.044","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}